RT Journal Article
SR Electronic
A1 Sinclair, Heather Q.
T1 Therapeutic Augmentation for Treatment-Resistant MDD
JF MD Conference Express
YR 2009
FD SAGE Publications
VO 9
IS 3
SP 24
OP 26
DO 10.1177/155989770903008
UL http://mdc.sagepub.com/content/9/3/24.abstract
AB Major depressive disorder (MDD) affects about 15 million adults in the United States. Within that population, only one-third of patients who are treated with first-line antidepressant therapies achieve remission [Trivedi MH, Papakostas G, Perlis R. APA 2009]. Therefore, therapeutic augmentation, the addition of nonantidepressant compounds to an antidepressant regimen, may be a more reasonable option for those patients with first-line treatment resistance. This article explores the issue of treatment resistance in MDD and possible management strategies.